Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma

Inclusion Criteria: Patients must have a diagnosis of non-B-cell, non-Hodgkin's lymphoma (including T-cell, null-cell, or NK-cell lymphoma, but excluding lymphoblastic lymphoma) Stage II, III, or IV disease requiring chemotherapy At least one site of measurable disease, 1.5 cm in diameter or greater Age > or = 18 years Absolute granulocyte count of at least 1500 cells/mm3, unless neutropenia is due to marrow infiltration by the tumor Platelet count of at least 100,000 cells/mm3 unless thrombocytopenia is due to marrow infiltration by tumor Creatinine less than 2 x upper limits of normal (ULN) Total bilirubin less than 2 x ULN (dose reduced vincristine and adriamycin required for bilirubin > 1.2 mg/dL) Echocardiogram (Echo) or multiple gate acquisition scan (MUGA) documenting a normal ejection fraction prior to chemotherapy Able to give informed consent Exclusion Criteria: Known central nervous system (CNS) involvement Known HIV disease Patients who are pregnant or nursing Any factor which might limit the patient's ability to provide informed consent Life expectancy < 3 months Patients who are unwilling to agree to use an effective means of birth control while on treatment